Gambin was the first EMBL Australia group leader appointed to Single Molecule Science. His signature method combines cell-free protein expression with two-colour single-molecule coincidence and fluctuation spectroscopy, which sidesteps purification entirely: proteins are expressed, labelled and measured in lysate, an order of magnitude faster than conventional interaction assays. The biology is protein self-association and aggregation — alpha-synuclein in Parkinson's, cardiac and muscular disease proteins — where the size distribution of oligomers, not the mean, is the quantity of interest. Positioned against the established body of NV-ensemble quantum sensing work — DEER, nanoscale NMR and T1 relaxometry protocols operating at pT/sqrt(Hz) field sensitivity — the conceptual overlap with quantum biosensing is the insistence on distributions over averages, and his aggregation systems (paramagnetic-species-generating, redox-active amyloid) are a plausible target for T1-relaxometry-based NV detection at pT/sqrt(Hz) in the near term.

Goldys was Deputy Director of the ARC Centre of Excellence for Nanoscale BioPhotonics and now leads a nanoscale biophotonics group in Biomedical Engineering. The programme is about extracting diagnostic information from very weak optical signals inside cells and tissue: luminescent and upconverting nanoparticle probes with long lifetimes that allow time-gated, background-free detection; hyperspectral unmixing of native cellular autofluorescence (NADH, FAD, porphyrins) as a completely label-free readout of cell state, which she has pushed toward clinical use in reproductive medicine and cancer; and nanoparticle-mediated therapy. Positioned against the established body of NV-ensemble quantum sensing work — DEER, nanoscale NMR and T1 relaxometry protocols operating at pT/sqrt(Hz) field sensitivity — time-gated luminescence and NV relaxometry are two solutions to the same problem — how to read a faint, specific signal out of an autofluorescent, optically hostile biological background — and her clinical translation experience is exactly the missing capability in most quantum-biosensing groups. Preferred attribute present: advanced/label-based imaging with a genuine human-application pathway.

Gooding is one of the world's most-cited biosensor scientists (inaugural editor-in-chief of ACS Sensors) and runs a group of over thirty researchers spanning surface chemistry, electrochemistry and nanomedicine. The sensing programme that matters here is the move from ensemble to digital, single-molecule-resolved detection: nanoparticle-tethered electrochemical sensors in which single binding events are counted rather than averaged, nanopore blockade sensors for protein biomarkers such as PSA, amplification-free nucleic-acid detection, and antifouling surface chemistries that make any of this work in real biological fluid. He has a strong commercialisation record (AgaMatrix glucose sensors). Positioned against the established body of NV-ensemble quantum sensing work — DEER, nanoscale NMR and T1 relaxometry protocols operating at pT/sqrt(Hz) field sensitivity — his single-molecule-counting philosophy is the biosensing analogue of moving from a pT/sqrt(Hz) NV ensemble to single-spin detection: in both cases the sensitivity gain comes from resolving individual events rather than improving an averaged signal. He is also the obvious collaborator for anyone trying to functionalise a diamond or nanoparticle quantum sensor for a real analyte.

Ladame develops biosensors and molecular diagnostic assays that detect cell-free circulating nucleic acid biomarkers (DNA/RNA) directly, without enzymatic amplification, for applications in early disease diagnosis and monitoring.

Soh's lab engineers aptamer- and SOMAmer-based electrochemical biosensors capable of real-time, continuous molecular measurement (drugs, metabolites, proteins) directly in living systems, aiming for closed-loop, quantitative point-of-care and in vivo diagnostics.

Whitesides' group pioneered soft lithography and paper-based microfluidics, and has long applied these tools to low-cost point-of-care diagnostic biosensors for global health settings. Included as a borderline, not-preferred biosensing case: the sensing target (colorimetric/electrochemical assays) is compelling but device-fabrication-centric rather than a cutting-edge-sensitivity physical sensor.